DapaCare investigates patient outcomes across CVRM diseases

CVRM diseases are a significant cause of patient morbidity and mortality

The global burden of CVRM diseases is vast and far-reaching. CVRM diseases cause a significant global burden to patients worldwide; an estimated 425 million people live with diabetes,1 64 million with HF,2 and almost 700 million with CKD stages 1–5.3 Together, these are the leading causes of death across the globe, resulting in up to 20 million deaths each year.4–7 Furthermore, due to many common risk factors and underlying disease pathologies, any one of these CVRM diseases can affect a patient’s risk of additional comorbidities.

CV disease is not only the number one cause of death globally, it is also the leading cause of death in people with CKD and people with diabetes.4,8 CV Disease
Despite improvements in the rate of CV death due to improved management of atherosclerotic conditions, there has been little or no change in HF-related CV death in the last 9 years.9
HF can be one of the first CV manifestations in patients with T2D,10 and 68% of older (mean age of 71) patients have evidence of left ventricular dysfunction 5 years after T2D diagnosis.11 Diabetes
In patients with T2D, age-adjusted prevalence of CKD is 38%. Patients with comorbid CKD and T2D have significantly worse outcomes than patients with CKD alone.12,13 Diabetes
Both reduced estimated glomerular filtration rate (eGFR) and increased albuminuria are independently associated with increased CV mortality. These associations are worse for patients with comorbid T2D. For patients with both diabetes and kidney disease, life expectancy can be reduced by up to 15 years for men and 17 years for women.13,14 CKD
HF can occur comorbidly in patients with CKD. As well as being a risk marker for decline in renal function, proteinuria is widely accepted as an independent risk factor for HF, CV morbidity and mortality.15,16 CKD

Evidence suggests that shared risk factors are still often not diagnosed or addressed4,7
This global and individual patient burden necessitates a therapeutic approach that can jointly address the underlying common risk factors and disease pathologies, and improve outcomes.

DapaCare represents our groundbreaking commitment to following the science of the sodium–glucose co-transporter 2 inhibitor dapagliflozin, to benefit patients with T2D, as well as patients with HF and CKD both with and without T2D.
Each DapaCare trial17–32 focuses on a different pathology, but each goes further to explore potential CV and renal benefits, pioneering a multifaceted approach to patient treatment.
DapaCare programme

Adverse events should be reported. For reporting adverse events, please click here

CKD, chronic kidney disease; CV, cardiovascular; CVRM, cardiovascular, renal, and metabolic; eGFR, estimated glomerular filtration rate; HF, heart failure; T2D, Type 2 diabetes


1. International Diabetes Federation. IDF Diabetes Atlas 2018. Available at: http://www.diabetesatlas.org/en/ (Accessed May 2020); 2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2017;390:1211–1259; 3. GBD Chronic Kidney Disease Collaboration. Lancet 2020;395:709–733; 4. World Health Organization. World Heart Day: Scale up prevention of heart attack and stroke. Available at: https://www.who.int/cardiovascular_diseases/world-heart-day/en/ (Accessed May 2020); 5. GBD 2017 Causes of Death Collaborators. Lancet 2018;392:1736–1788; 6. Ogurtsova K, et al. Diabetes Res Clin Pract 2017;128:40–50; 7. World Health Organization. CVD fact sheets 2017. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (Accessed May 2020); 8. Pálsson R, Patel UD. Adv Chronic Kidney Dis 2014;21:273–280; 9. Cheng YJ, et al. Diabetes Care 2018;41:2306–2315; 10. Shah AD, et al. Lancet Diabetes Endocrinol 2015;3:105–113; 11. Faden G, et al. Diabetes Res Clin Pract 2013;101:309–316; 12. Wu B, et al. BMJ Open Diabetes Res Care 2016;4:e000154; 13. Wen CP, et al. Kidney Int 2017;92:388–396; 14. Fox C, et al. Lancet 2012;380:1662–1674; 15. Currie G, et al. Int J Nephrol Renovasc Dis 2014;7:13–24; 16. He J, et al. J Am Heart Assoc 2017;6:6005336; 17. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT03036124 (Accessed October 2020); 18. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT03036150 (Accessed October 2020); 19. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01730534 (Accessed October 2020); 20. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02547935 (Accessed October 2020); 21. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02993614 (Accessed October 2020); 22. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03030235 (Accessed October 2020); 23. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02653482 (Accessed October 2020); 24. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03152084 (Accessed October 2020); 25. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03338855 (Accessed October 2020); 26. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03387683 (Accessed October 2020); 27. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03190694 (Accessed October 2020); 28. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03619213 (Accessed October 2020); 29. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03877237 (Accessed October 2020); 30. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03877224 (Accessed October 2020); 31. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT04363697 (Accessed October 2020); 32. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT04564742 (Accessed October 2020)